Newsfeeds Archive - Spark Newswire

1 minute read

NewAmsterdam Pharma Presents New Clinical And Preclinical Data On Obicetrapib’s Impact On Key Risk Factors For Cardiovascular Disease At Upcoming Medical Meetings

May 21, 8:25 AM

-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib's impact on key lipid and lipoprotein biomarkers -- -- On track to report topline data from Phase 3

NAMS

2 minute read

NewAmsterdam Pharma Q1 EPS $(1.06) Vs $(0.51) YoY

By Benzinga Newsdesk

May 9, 9:04 AM

First Quarter Financial ResultsCash Position: As of March 31, 2024, NewAmsterdam recorded cash of $481.1 million, compared to $340.5 million as of December 31, 2023. The increase in cash is primarily driven by the

NAMS

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

April 29, 4:31 PM

Gainers GeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday’s after-market session. The market value of…

COSM

4 minute read

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday’s Mid-Day Session

By Avi Kapoor

January 19, 2:05 PM

Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.

ABSI

2 minute read

World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday

By Avi Kapoor

January 19, 11:20 AM

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of World Acceptance Corporation (NASDAQ: WRLD) rose sharply during Friday’s session following upbeat quarterly results.

ALLY

2 minute read

Cholesterol Player NewAmsterdam Pharma’s Obicetrapib Is A Potential Blockbuster In Cardiovascular Market: Bullish Analyst Says

By Vandana Singh

January 16, 3:48 PM

Piper Sandler's coverage on NewAmsterdam Pharma and its clinical-stage therapy, Obicetrapib, a potent CETP inhibitor targeting cardiovascular health. With a unique mechanism, superior efficacy, and market potential, Piper gives an Overweight rating and a $37 price target.

NAMS

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

January 15, 9:05 AM

Gainers Jin Medical International (NASDAQ:ZJYL) shares moved upwards by 19.2% to $93.0 during Monday’s pre-market session. The company’s…

AHG

1 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

January 10, 5:31 PM

Gainers Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 6.7% to $0.26 during Wednesday’s after-market session. The company’s market…

ATNF

3 minute read

Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Avi Kapoor

January 10, 2:06 PM

Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results.

ACRS

2 minute read

NewAmsterdam Pharma Reports 9-Month Revenue Of $13.3M, 9- Month EPS Of $(1.55)

By Benzinga Newsdesk

November 13, 9:31 AM

Financial HighlightsCash Position: As of September 30, 2023, NewAmsterdam recorded cash of $368.3 million (€347.7 million), compared to $467.7 million (€438.5 million) as of December 31, 2022. The decrease reflects cash

NAMS